Gilead Sciences has signed a definitive agreement to acquire EpiTherapeutics ApS, a privately-held Danish company, for $65 million.   EpiTherapeutics has a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. The company’s lead preclinical compounds are being studied for the treatment of certain cancers.   “Epigenetics is a promising area of research and the EpiTherapeutics team is a recognized scientif...